🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  2. 68Ga-NODAGA-SNA006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 2 small molecule active

    1 trial

  3. 68Ga-NY104 PET/CT

    Peking University Third Hospital

    Clear Cell Renal Cell Carcinoma

    phase 2 other active

    1 trial

  4. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. 68Ga-Pentixafor

    Peking University Third Hospital

    Cushing s Syndrome

    phase 2 small molecule active

    1 trial

  6. 6QC-ICG, Placebo for 6QC-ICG

    Disc Medicine

    Breast cancer

    phase 2 small molecule active

    1 trial

  7. A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  8. A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  9. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  10. A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

    Shanghai Antengene Corporation Limited

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  11. A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  12. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  13. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  14. A.1 Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  15. AB8939, Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    AB Science

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  16. AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALEN®

    Lacuna Pharma Pty Ltd

    Idiopathic Sudden Sensorineural Hearing Loss

    phase 2 small molecule active

    1 trial

  17. ACT-20-MSC

    Aspire Biopharma Holdings

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  18. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  19. ADSC01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Connective Tissue Diseases

    phase 2 mab active

    1 trial

  20. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  21. AK0529

    Shanghai University of Traditional Chinese Medicine

    RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

    phase 2 small molecule completed

    1 trial

  22. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  24. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources